Taking a digital health company into a new country brings a new regulatory classification, a different payer or reimbursement structure, and often a new definition of who the buyer actually is. Companies that approach international expansion as a translation exercise waste a year and a market entry budget learning that lesson the hard way. We create market entry and localization plans based on how care is truly funded and delivered in the country you're entering, not simply how your product sounds in another language.
The Challenge
Regulatory classification starts over in each country, and approval at home carries no weight abroad
A product that clears as low-risk software in the US can land in a stricter device or data category the moment it crosses into a market with different medical software rules or data residency requirements. Teams that assume regulatory work is done once it's done everywhere lose months discovering a new filing requirement mid-launch. Every market entry plan has to start with a fresh regulatory read for that specific country, not an extension of the domestic one.
In a new market, the buyer and payer are often different people, and neither resembles your US customer
A product sold direct-to-consumer in the US might be a provider-referred or government-reimbursed product in a market with national health coverage, which changes who you're marketing to and what convinces them. Companies that port their US positioning wholesale end up pitching a self-pay consumer message into a market where almost nobody self-pays for that category of care.
Localization is treated like translation, but clinical and trust-building language rarely survives word-for-word translation
Health-related messaging carries cultural weight that a straight translation misses – how a country's population talks about mental health, chronic conditions, or preventive care shapes what language builds trust versus what reads as foreign or clinical in the wrong way. A translated US landing page routinely underperforms a page written from scratch for that market's health context. Getting this wrong doesn't just underperform; it can actively damage credibility with the providers or patients you need to trust the brand quickly.
Companies manage new-market launches from the home office without a local presence, and every channel reveals it
Local search behavior, provider referral patterns, and even which channels a health buyer trusts vary enough by country that a headquarters team managing the launch remotely, without local media relationships or on-the-ground validation, consistently underperforms a market entry with even minimal local presence. Budget gets spent on channels that work at home and underperform abroad because nobody tested the local assumption before scaling spend.
How We Support You
We begin with market prioritization before moving into market entry – evaluating candidate countries by regulatory complexity, reimbursement structure, competitive density, and how closely their buying process matches what your team already knows how to sell.
For the market or markets selected, we create a country-specific regulatory and reimbursement map – including your product's classification, applicable data residency or privacy requirements, and how care in that category is actually funded, whether through national health coverage, private insurance, or self-pay.
We then design the entry model: direct entry through a local team, a distribution or channel partner, or a hybrid, depending on how much local trust the category demands and how quickly you need to move.
Our localization work extends beyond translation – we reshape messaging around how people in that market genuinely discuss the health condition or category you serve, using local clinical and cultural input instead of translating US copy. This work runs alongside our creative practice, ensuring the localized brand still feels like a single company rather than a disconnected collection of regional identities.
For channels, we test local media and acquisition options at limited scale before committing the launch budget, because the channels powering your US growth model – a particular paid social platform or specific search behavior – may not transfer, and markets with different provider referral patterns may require an entirely different channel mix to reach the true decision-maker.
For measurement, we establish market-specific unit economics from day one instead of carrying over your US CAC and LTV targets, since acquisition costs, sales cycles, and payer mix vary enough between countries that a shared benchmark creates more confusion than value.
Unlike an agency following a generic international expansion checklist, we first shape the plan around how care is actually funded and delivered in that country, then build the marketing plan.
What we deliver
- Market prioritization scorecard – regulatory complexity, reimbursement structure, and competitive density scored across candidate countries
- Country-specific regulatory and reimbursement map – product classification, data rules, and how care in your category gets paid for
- Entry model recommendation – direct, partner-led, or hybrid, matched to how much local trust-building the category requires
- Locally-built messaging and creative, developed from that market's health context rather than translated from US copy
- Market-specific unit economics and a small-scale channel testing plan, tracked against its own baseline rather than a US benchmark
Most international expansion plans appear to fail during translation, but the underlying mistake comes earlier – assuming the buyer, payer, and regulatory category abroad match those at home. If that assumption is wrong, no amount of localized copy can correct it.
Our Methodology
International expansion follows the same 90-day sprint, with the regulatory and market-prioritization work front-loaded before any creative is developed. The first 30 days focus on market prioritization and, for the selected market, the regulatory and reimbursement map defining what is genuinely possible in that country. Days 30 through 60 develop the entry model and localized go-to-market plan – messaging, channel selection, and entry structure – guided by that regulatory map rather than a standard international playbook.
Days 60 through 90 shift into small-scale market testing: launching localized messaging and the channel mix with limited spend, assessing early signals against market-specific benchmarks, and refining the approach before committing the full launch budget. This order – regulatory and payer realities first, followed by creative and channels – reverses how most companies pursue international growth, where marketing is created first and regulatory and payer issues emerge only after the launch is already underway.
Because market entry results rely on sales or provider-referral cycles that unfold over months, most engagements continue beyond the first sprint into an ongoing market operations phase, making the 90-day sprint the foundation rather than the entire engagement.
Our Process
The first 30 days focus on market prioritization and regulatory mapping. We evaluate candidate countries against your product and resources, then develop the regulatory, data, and reimbursement map for your selected market. Before committing any launch spend, you receive a clear answer on what operating in that country actually requires.
Days 30 through 60 are dedicated to building the entry model and localized go-to-market plan. We require input from your product and clinical teams to confirm what the product can support within the new market's regulatory category, plus your finance team to validate the unit economics the entry must achieve.
Days 60 through 90 conduct the small-scale market test – localized messaging paired with a limited channel launch, measured against market-specific benchmarks instead of your US figures. Throughout the test period, we report weekly on early signals across channels and segments.
Complete market entry and scale-up generally continue far beyond the first 90 days because provider-referral and reimbursement-led sales cycles unfold over months rather than weeks. Most engagements last three to six months for the initial development and testing phase, followed by ongoing market operations as the new geography grows.
- Regulatory and reimbursement clarity before launch spend
- Market-specific channel mix built from real test data, not assumption
- Localized brand credibility with in-market providers and patients
- Sustainable unit economics benchmarked to the new market, not the US
If your digital health company needs international growth leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does an international expansion engagement cost a digital health company?
Cost depends on how many markets you're assessing and the depth of regulatory and reimbursement mapping required for the market you select – entering one market with an established payer system is scoped differently from prioritizing multiple markets across several new regions. Pricing includes strategy and market-testing work; local legal filings, entity formation, and paid media spend are separate costs that differ by country.
How much time does launching in a new international market require?
Regulatory mapping and go-to-market planning generally require 60 to 90 days before the first localized launch is live, though the schedule may extend when the target market has a more complicated reimbursement or device classification process. Getting a meaningful view of whether market entry is succeeding – beyond initial signals – usually requires one complete sales or provider-referral cycle in that market, which may take three to twelve months depending on the category.
How does the international growth team collaborate with our internal team?
We require direct access to your product and clinical leads to confirm what the product can legally and practically deliver under the new market's regulatory category, as well as your finance team to align on the unit economics required in that market. Local legal and entity formation typically engages in-country counsel whom we coordinate with, rather than being a function we provide directly.
What distinguishes Winston Francois from a standard international marketing agency?
Most international marketing agencies begin with translation and localized creative. We begin with the target market's regulatory classification and reimbursement structure because those factors establish who the buyer really is and which claims the product can support – creative and channel strategy follow once that foundation is clear, never before.
How is ROI measured for international expansion?
We develop market-specific unit economics – CAC, sales cycle duration, and channel-level conversion – benchmarked against that market instead of your US figures, because payer mix and purchasing behavior vary enough across countries that one shared benchmark gives a distorted picture. Early measurement examines channel and message signals throughout the small-scale test; later measurement tracks market-level revenue and unit economics against the targets in the entry plan.
Which type of digital health company is prepared for international expansion?
This is designed for digital health companies in the 5M to 100M ARR range that have a validated domestic model and enough resources for a genuine market entry – including regulatory filings, possible in-country hires or partners, and a launch budget distinct from domestic marketing spend. It is not a good fit for companies still establishing product-market fit at home, because international expansion introduces complexity that a domestic business still finding stability cannot absorb.
